Characterization of factor VIII antibody epitopes from hoemophilin A patients using cellulose bound FVIII peptide libraries;Charakterisierung von faktor-VIII-antikörperepitopen mit faktor-VIII-peptid-bibliotheken

Hamostaseologie

Volumn 23, Issue 1, 2003, Pages 13-17

  Albert, T ^a   Lange, S ^a   Oldenburg, J ^b   Graw, J ^c   Schramm, W ^d   Hanfland, P ^a   Brackmann, H H ^a   Schwaab, Rainer ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Inst Transfusionsmed/Immunhamatol   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Factor VIII; FVIII peptide libraries; Inhibitory antibody epitope

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; CELLULOSE; EPITOPE; NEUTRALIZING ANTIBODY; PEPTIDE LIBRARY; PROCOAGULANT;

AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; DISEASE COURSE; DISEASE SEVERITY; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; REVIEW;

EID: 0037314020     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1619566     Document Type: Review

References (17)

1. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors - twenty years Bonn Protocol. Vox Sang 1996; 70(Suppl 1): 30-5.
2. Fijnvandraat K, Celie PH, Turenhout EA, ten Cate JW. van Mourik JA, Mertens K, Peters M, Voorberg J. A human alloantibody interferes with binding of factor IXa to the factor VIII light chain. Blood 1998; 91: 2347-52.
3. Fulcher CA, de Graaf Mahoney S,Roberts JR, Kasper CK, Zimmermann TS. Localization of human factor VIII inhibitor epitopes to two polypeptide fragments; Proc Natl Acad Sci USA 1985; 82: 7728-32.
4. Frank R. SPOT synthesis: an easy technique for the positionally addressable, parallel chemical synthesis on a membrane support. Tetrahedron 1992; 48: 9217-32.
5. Gilles JG. Saint-Remy JMR. Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies; J Clin Invest 1994; 94: 1496-1505.
6. Hay CRM, Ollier W, Pepper L, Cumming A, Keeney S, Goodeve AC, Colvin BT, Hill FGH, Reston FE, Peake IR, from the UKHCDO Inhibitor Working Party. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe Haemophilia A. Thromb Haemost 1997; 77: 234-7.
7. Healey JF, Lubin IM, Nakai H, Saenko EL, Hoyer LW, Scandella D, Lollar P. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem 1995; 270: 14505-9.
8. Healey JF. Barrow RT, Tamim HM, Lubin IM, Shima M, Scandella D, Lollar P. Residues Glu2181-Va12243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood 1998; 92: 3701-9.
9. Nogami K, Shima M, Nakai H, Tanaka I, Suzuki H, Morichika S, Shibata M, Saenko EL, Scandella D, Giddings JC, Yoshioka A. Identification of a factor VIII peptide, residues 315-2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum effect. Br J Haematol 1999; 107: 196-203.
10. Oldenburg J, Picard J, Schwaab R, Brackmann H-H, Tuddenham EGD, Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997; 77: 238-42.
11. Pemberton S, Lindley P, Zaitsev V, Card G, Tuddenham EGD, Kemball-Cook. A molecular model for the triplicated a domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood 1997; 89: 2413-21.
12. Scandella D, Mattingly M, Prescott R. A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind to A2. Blood 1993; 82: 1767-75.
13. Schneider-Mergener J, Kramer A, Reineke U. Peptide libraries bound to continuous cellulose membranes: tools to study molecular recognition. In: Cortese R (ed). Combinatorial Libraries - Synthesis, Screening and Application Potential. Berlin: Walter de Gruyter 1996: 53-68.
14. Schwaab R, Brackmann H-H, Meyer C, Seehafer J, Kirchgesser M, Haack A, Olek K, Tuddenham EGD, Oldenburg J. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-6.
15. Spiegel PC Jr, Jacquemin M, Saint-Remy JM, Stoddard BL, Pratt KP: Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII. Blood 2001; 98: 13-9.
16. Stoilova-McPhie S, Villoutreix BO, Mertens K, Kemball-Cook G, Holzenburg A. 3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heretodimer within a 3-dimensional density map derived by electron crystallography. Blood 2002; 99: 1215-23.
17. Villard S, Piquer D, Raut S, Leonetti JP, Saint-Remy JM, Granier C.: Low molecular weight peptides restore the procoagulant activity of factor VIII in the presence of the potent inhibitor antibody ESH8. J Biol Chem 2002; 277: 27232-9.